Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free IDHC Stock Alerts

Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics logo
GBX 0.53 -0.02 (-3.28%)
As of 11:59 AM Eastern
Compare

IDHC vs. AGL, PRM, GENI, VRCI, and DMTR

Should you buy Integrated Diagnostics stock or one of its competitors? Integrated Diagnostics's main competitors and comparable companies include ANGLE (AGL), Proteome Sciences (PRM), GENinCode (GENI), Verici Dx (VRCI), and Deepmatter Group (DMTR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Integrated Diagnostics compare to ANGLE?

ANGLE (LON:AGL) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, ANGLE had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Integrated Diagnostics. ANGLE's average media sentiment score of 0.75 beat Integrated Diagnostics' score of 0.00 indicating that ANGLE is being referred to more favorably in the media.

Company Overall Sentiment
ANGLE Positive
Integrated Diagnostics Neutral

ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, meaning that its stock price is 57% less volatile than the broader market.

Integrated Diagnostics has a net margin of 16.49% compared to ANGLE's net margin of -1,444.04%. Integrated Diagnostics' return on equity of 39.61% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-1,444.04% -191.36% -29.89%
Integrated Diagnostics 16.49%39.61%9.69%

17.5% of ANGLE shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 2.7% of ANGLE shares are held by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Integrated Diagnostics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.62M2.89-£21.76M-£4.80N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

Summary

Integrated Diagnostics beats ANGLE on 9 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Proteome Sciences had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 beat Proteome Sciences' score of -0.71 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Proteome Sciences Negative
Integrated Diagnostics Neutral

Proteome Sciences has a beta of 0.157, indicating that its share price is 84% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, indicating that its share price is 57% less volatile than the broader market.

Integrated Diagnostics has a net margin of 16.49% compared to Proteome Sciences' net margin of -61.46%. Integrated Diagnostics' return on equity of 39.61% beat Proteome Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-61.46% 23.85% -19.25%
Integrated Diagnostics 16.49%39.61%9.69%

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.77M1.13-£4.08M-£1.04N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

Summary

Integrated Diagnostics beats Proteome Sciences on 11 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to GENinCode?

Integrated Diagnostics (LON:IDHC) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

In the previous week, GENinCode had 5 more articles in the media than Integrated Diagnostics. MarketBeat recorded 5 mentions for GENinCode and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 beat GENinCode's score of -0.31 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Integrated Diagnostics Neutral
GENinCode Neutral

7.7% of Integrated Diagnostics shares are owned by institutional investors. Comparatively, 11.4% of GENinCode shares are owned by institutional investors. 78.4% of Integrated Diagnostics shares are owned by company insiders. Comparatively, 8.4% of GENinCode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Integrated Diagnostics has a beta of 0.432, meaning that its share price is 57% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Integrated Diagnostics has a net margin of 16.49% compared to GENinCode's net margin of -202.42%. Integrated Diagnostics' return on equity of 39.61% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics16.49% 39.61% 9.69%
GENinCode -202.42%-481.34%-63.99%

Integrated Diagnostics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00
GENinCode£3.08M1.76-£6.10M-£2.08N/A

Summary

Integrated Diagnostics beats GENinCode on 9 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to Verici Dx?

Verici Dx (LON:VRCI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M1.40-£6.56M-£0.90N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

15.9% of Verici Dx shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 1.2% of Verici Dx shares are owned by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Verici Dx had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 beat Verici Dx's score of -1.58 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Verici Dx Very Negative
Integrated Diagnostics Neutral

Verici Dx has a beta of 1.222, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, suggesting that its stock price is 57% less volatile than the broader market.

Integrated Diagnostics has a net margin of 16.49% compared to Verici Dx's net margin of -223.60%. Integrated Diagnostics' return on equity of 39.61% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-223.60% -127.57% -26.14%
Integrated Diagnostics 16.49%39.61%9.69%

Summary

Integrated Diagnostics beats Verici Dx on 9 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to Deepmatter Group?

Deepmatter Group (LON:DMTR) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

7.7% of Integrated Diagnostics shares are held by institutional investors. 78.4% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Integrated Diagnostics has a net margin of 16.49% compared to Deepmatter Group's net margin of 0.00%. Integrated Diagnostics' return on equity of 39.61% beat Deepmatter Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Deepmatter GroupN/A N/A N/A
Integrated Diagnostics 16.49%39.61%9.69%

Integrated Diagnostics has higher revenue and earnings than Deepmatter Group. Deepmatter Group is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deepmatter Group£1.04M0.00N/A-£0.30N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

In the previous week, Deepmatter Group's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
Deepmatter Group Neutral
Integrated Diagnostics Neutral

Summary

Integrated Diagnostics beats Deepmatter Group on 8 of the 8 factors compared between the two stocks.

Get Integrated Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDHC vs. The Competition

Export
MetricIntegrated DiagnosticsLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£3.08M£10.67B£7.10B£2.83B
Dividend Yield1.55%1.45%2.54%6.26%
P/E Ratio0.0031.75273.96366.33
Price / Sales0.00423.33634.6689,071.63
Price / CashN/A27.3227.2227.89
Price / Book0.006.8711.096.96
Net Income£4.01T£57.48B£3.49B£5.89B
7 Day Performance1.53%-0.29%-2.30%-0.62%
1 Month Performance2.71%7.02%-7.05%-1.07%
1 Year Performance2.91%29.36%5.65%22.84%

Integrated Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDHC
Integrated Diagnostics
N/AGBX 0.53
-3.3%		N/A+2.4%£3.08M£9.17B0.006,692
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-14.5%£7.58M£2.62MN/A650
PRM
Proteome Sciences
N/AGBX 1.69
+20.7%		N/A-35.8%£5.93M£3.77MN/A240
GENI
GENinCode
N/AGBX 0.70
-20.0%		N/A-82.0%£5.27M£3.08MN/A2,300
VRCI
Verici Dx
N/AGBX 0.21
-6.7%		N/AN/A£4.80M£3.66MN/A19

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IDHC) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
Nvidia’s record quarter could send this new type of AI soaring
Nvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...
Brownstone Research | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...
Stansberry Research | Sponsoredtc pixel
I've seen this movie before (last time: 17,556%)
My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...
Crypto 101 Media | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel